


## Abarelix

## Chemical Properties

CAS No. :	183552-38-7
Formula:	C72H95ClN14O14
Molecular Weight:	1416.06
Storage:	Keep away from moisture Powder: -20°C for 3 years   In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



## Biological Description

Description	Abarelix (PPI 149) is a potent gonadotrophin-releasing hormone (GnRH) antagonist, which is used for prostate cancer treatment.
Targets(IC50)	GNRH Receptor
In vitro	Abarelix, at concentrations of 30 and 300 µg/mL, significantly increases histamine release[1]. It rapidly and considerably lowers follicle-stimulating hormone levels below those achieved by LHRH agonists. As the inaugural GnRH antagonist developed, Abarelix achieves fast and sustained testosterone reductions to castrate levels without requiring concurrent antiandrogen therapy, exhibiting a remarkably low short-term complication rate[2]. Unlike other treatments, it avoids the testosterone surge that can exacerbate symptoms or disease progression, particularly in patients with metastatic, symptomatic conditions, facilitating quicker medical castration[3].

## Solubility Information

Solubility	DMSO: 14.2 mg/mL (10.03 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	----------------------------------------------------------------------------------------------------------------------------

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	0.7062 mL	3.5309 mL	7.0618 mL
5 mM	0.1412 mL	0.7062 mL	1.4124 mL
10 mM	0.0706 mL	0.3531 mL	0.7062 mL
50 mM	0.0141 mL	0.0706 mL	0.1412 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Koechling W, et al. A novel GnRH antagonist, causes minimal histamine release compared with abarelix in an ex vivo model of human skin samples. *Br J Clin Pharmacol.* 2010 Oct;70(4):580-7.

Zhao L, Sun X, Hou C, et al. CPNE7 promotes colorectal tumorigenesis by interacting with NONO to initiate ZFP42 transcription. *Cell Death & Disease.* 2024, 15(12): 896.

Kirby RS, et al. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. *BJU Int.* 2009 Dec;104(11):1580-4.

Debruyne F, et al. Abarelix for injectable suspension: first-in-class releasing hormone antagonist for prostate cancer. *Future Oncol.* 2006 Dec;2(6):677-96.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481